The issue with Samsung from a credibility standpoi
Post# of 154722

But BTD, BLA acceptance, major licensing deal, investment from a top tier pharma fund, -- even a top-tier pharma player on the BOD -- those will undoubtedly move the credibility needle.
(Even one mainstream publication mentioning LERO would be a big step up from what we have today).

